A condition, known commonly as "black urine disease" or Alkaptonuria is a rare genetic disorder involving protein metabolism, and it has its root in the mutation of the homogentisate 1,2-dioxygenase gene, which in turn causes homogentisic acid accumulation in the body. The appearance of dark urine after exposure to air is due to this kind of accumulation; however, a variety of symptoms can be expected, such as joint stiffness, changes in pigmentation, and other long-term health complications. Although the prevalence has been estimated to be between 1 in 250,000 and 1 in 1 million people in the United States, its effects are indeed high on those affected.

Alkaptonuria is an autosomal recessive disease, meaning that the child must inherit a defective copy of the HGD gene from both parents. If both parents are carriers, their offspring have a 25% chance of inheriting two faulty genes and developing alkaptonuria. The condition is genetic but is often not diagnosed for years because it progresses slowly and its early symptoms appear to be harmless.

Symptoms of Alkaptonuria

The most characteristic and common initial symptom of alkaptonuria is dark urine. The reason for this is due to the fact that excess HGA is excreted in the urine and upon oxidation in the presence of air, it gives the urine a brown or black color. Though it is often considered cosmetic, the long-term accumulation of HGA within the connective tissues produces more complicated health problems.

Progressive joint pain and stiffness: The accumulation of HGA in cartilage leads to early-onset osteoarthritis, making movement increasingly difficult over time.

Skin and eye pigmentation changes: Affected individuals may develop bluish or grayish discoloration of the sclera (white part of the eye) and the skin, particularly in areas exposed to friction.

Cardiovascular and respiratory problems: With age, HGA accumulation can lead to valve calcifications in the heart and stiffening of connective tissues in the respiratory tract, which can cause problems in middle and old age.

Decreased mobility and spinal problems: The spine may become stiff and painful due to chronic cartilage degeneration.

These symptoms usually begin to manifest during adulthood, leading to severe complications in a person's 40s or 50s and significantly affecting the quality of their life.

How is Alkaptonuria Diagnosed?

Because of its rarity, alkaptonuria is often mistaken or overlooked early in life. However, there are several ways to confirm the condition:

Urine Testing: The gold standard in the diagnosis is the testing of urine samples for high levels of homogentisic acid via gas chromatography. In case of oxidation, which changes the color of urine to black, it is indicative of alkaptonuria.

Genetic Testing: Confirmatory genetic testing reveals mutations of the HGD gene to diagnose the condition conclusively.

Blood Tests: High levels of HGA in the blood can be used as further evidence.

Imaging Studies: X-rays and MRIs will expose cartilage and joint damage characteristic of alkaptonuria.

Management of Alkaptonuria: Is There A Cure?

At present, there is no cure for alkaptonuria; however, various treatment approaches can reduce its symptoms and slow the disease's progress:

Nitisinone Therapy: Nitisinone is a drug that inhibits the production of HGA. It has been shown to reduce HGA levels and slow tissue damage. However, it needs to be taken under close medical supervision because of potential side effects.

Low-Protein Diet: Since HGA is a byproduct of protein metabolism, reducing protein intake—especially foods rich in tyrosine and phenylalanine—may help decrease HGA production.

Pain Management: OTC pain relievers and anti-inflammatory medications can be used to relieve joint pain and stiffness.

Physical Therapy: Exercise regularly, as it may improve mobility and strengthen muscles, thus reducing strain on affected joints.

Surgical Interventions: Most people with alkaptonuria develop severe osteoarthritis necessitating joint replacement in their old age. Also, some may require heart valve replacement surgery if cardiovascular complications develop.

Life with Alkaptonuria

Although alkaptonuria is not fatal, it severely affects the quality of life. The progressive deterioration of the joints and associated symptoms can make everyday activities difficult, requiring lifestyle changes and medical interventions. The disease may cause premature aging of the joints, requiring walking aids and mobility assistance earlier than expected.

Ongoing research will continue to work on improving the treatment options by focusing on gene therapy and alternative enzyme replacement therapies. However, because of its rarity, the clinical trials and research remain sparse.

As genetic research advances, more hope for better management and possible curative approaches for alkaptonuria exists. Scientists are searching extensively for enzyme replacement therapies and innovative drugs that can target the root cause of the disorder. Being aware and being diagnosed early helps individuals better their condition and ultimately have better long-term health outcomes.

Alkaptonuria is a striking example of how one gene mutation can have widespread effects on the body. Though still a rare and often misunderstood condition, growing awareness and advances in treatment are paving the way for better care. If you or a loved one suspect symptoms of alkaptonuria, it is essential to seek early diagnosis and medical guidance to manage the disease effectively and preserve quality of life.

Blood disorders are often misunderstood; many people think that all serious blood-related conditions are a form of cancer. This misunderstanding is particularly common when it comes to sickle cell disease. Both sickle cell disease and blood cancers affect blood cells and can lead to significant health complications, but they are fundamentally different, with distinct causes, treatment approaches, and long-term outcomes. Understanding these differences is important not only for patients and their families but also for awareness and ensuring timely medical care.

Sickle cell disease is an inherited genetic disorder that develops in a person who inherits abnormal hemoglobin genes from both parents. Hemoglobin is the protein in red blood cells responsible for carrying oxygen throughout the body. People with sickle cell disease have red blood cells that become rigid and crescent or "sickle" shaped instead of their normal round structure. These abnormal cells can block blood vessels, reduce oxygen delivery to tissues, and break down more rapidly than healthy red blood cells. As a result, patients may experience chronic anemia, episodes of severe pain, recurrent infections, organ damage, and other complications.

How Blood Cancers Differ From Sickle Cell Disease

Blood cancers are cancers that originate in the blood-forming tissues, such as the bone marrow and lymphatic system. The most common types include leukemia, lymphoma, and multiple myeloma. Unlike sickle cell disease, blood cancers are generally not inherited and are caused by DNA mutations that occur during a person's lifetime. These mutations cause abnormal blood cells to grow, crowding out healthy cells and interfering with the body's ability to fight infections, carry oxygen, or control bleeding.

The two conditions are different, but some symptoms may overlap. For instance, tiredness, weakness, recurrent infections, and anemia can occur in both sickle cell disease and certain blood cancers. However, the underlying reasons are entirely different. In sickle cell disease, symptoms arise because of abnormal hemoglobin and sickling of red blood cells. In blood cancers, symptoms result from the uncontrolled growth of malignant cells within the bone marrow or lymphatic system.

Difference in Diagnosis And Treatment

Diagnoses for both diseases differ. Sickle cell disease is usually identified through specialized blood tests that detect abnormal hemoglobin. In many cases, it can be diagnosed early in childhood. Blood cancers require a combination of blood investigations, bone marrow examinations, imaging studies, and specialized laboratory tests to establish the diagnosis and determine the specific cancer subtype.

The treatment approaches for these disorders reflect these differences. Management of sickle cell disease focuses on preventing complications, controlling symptoms, reducing pain crises, preventing infections, and improving quality of life. Certain patients may benefit from advanced therapies, including stem cell transplantation and emerging gene-based treatments.

Why Awareness Matters

Blood cancer treatment depends on the type and stage of disease and may require chemotherapy, targeted therapy, immunotherapy, stem cell transplantation, radiation therapy, or newer cellular therapies such as CAR-T cell therapy. The treatment plan is individual-based, depending on factors such as the specific cancer subtype, disease burden, patient age, pre-existing conditions, and overall health.

While medical advances are transforming outcomes for both conditions, improved screening infrastructure and programs, better care, advances in transplantation, targeted therapies and innovative cellular treatments are helping patients live longer and healthier than ever before. That said, awareness remains the first step towards better outcomes. Knowing the differences between sickle cell disease and blood cancers can help reduce confusion, support early diagnosis, and timely intervention.

(By Dr. Narendra Agrawal, Sr. Consultant – Hemato Oncology & Bone Marrow Transplant, Rajiv Gandhi Cancer Institute & Research Centre (RGCIRC), New Delhi)

GLP-1 drugs like Ozempic, Mounjaro, and Wegovy may not only aid weight loss and improve diabetes control but could also help men with obesity improve their fertility, according to new research.

Obesity is a well-established risk factor for infertility in both men and women. The findings, presented at ENDO 2026, the Endocrine Society's annual meeting in Chicago, suggest that GLP-1 medications do not harm male hormones or fertility, even with long-term use.

Researchers from the University Hospitals Coventry and Warwickshire and Warwick Medical School in the UK found that GLP-1 drugs may improve testosterone levels and sperm quality in men with obesity-related low testosterone while addressing the underlying metabolic effects of obesity.

"This work supports a shift away from prescribing testosterone replacement in men with obesity and low testosterone and toward treating the underlying cause—excess weight and poor metabolic health—which can naturally restore hormone levels and preserve fertility," said lead researcher and endocrinologist Pratibha Natesh of Warwick Medical School.

What Did The Study Find?

Also read: Ozempic-Like Weight-Loss Drugs May Cut Breast Cancer Risk By A Third, Finds Research

The researchers analyzed published randomized controlled trials comparing GLP-1 medications with either placebo or other treatments in men aged 18 to 65 years.

The review focused primarily on changes in testosterone and other hormones involved in testicular function. Researchers also evaluated sperm quality, body weight, blood sugar levels, cholesterol, and overall metabolic health.

To minimize bias, two independent reviewers assessed the studies, with five clinical trials meeting the eligibility criteria.

Overall, the findings showed that GLP-1 drugs had no negative impact on reproductive hormones, sexual function, or sperm quality.

For instance, a 24-week study of semaglutide found improvements in sperm morphology and cholesterol levels while maintaining stable testosterone and hormone levels.

Another 16-week study of liraglutide in men with obesity-related low testosterone showed increases in testosterone and associated reproductive hormones. Participants also experienced better overall health outcomes compared with those receiving testosterone replacement therapy alone.

More Research Needed

Read More: Mayim Bialik Says Just One GLP-1 Shot Triggered ‘Nightmare’ Side Effects

Despite the encouraging findings, Natesh cautioned that the number of available studies remains small and results vary across trials. Larger, well-designed studies are needed to better understand the effects of GLP-1 drugs on male fertility.

She also emphasized that most of the reproductive benefits observed are likely indirect and that GLP-1 medications have not been evaluated as treatments for male infertility or hypogonadism.

Nevertheless, the researchers hope the findings will help patients and physicians make more informed decisions about GLP-1 medications used for weight management and diabetes treatment.

"Improving metabolic health can have positive effects far beyond weight alone," Natesh said.

What Are GLP-1 Drugs

GLP-1 receptor agonists are medications to control high blood sugar in people with type 2 diabetes.

These therapies help by:

• Increasing insulin release when blood sugar rises
• Delaying stomach emptying
• Reducing appetite
• Decreasing glucagon production
• Improving weight loss

Dr. Uthra, a diabetologist and Sr. consultant at Dr.Mohan’s Diabetes Speciality Centre, in Chennai, told HealthandMe that while GLP-1 therapies help control blood sugar, beyond this, these treatment regimens provide many more benefits.

Research shows that these medications can reduce the risk of major cardiovascular events such as heart attack and stroke.

In addition, GLP-1 therapies help in weight reduction. Obesity is also linked to diabetes and heart disease. Hence, GLP-1 therapies help to reduce weight and the risk of developing heart diseases, the expert said.

Déjà Vu is a feeling of sensation when one person feels that they have felt or witnessed the same situation before, just like a single incident is happening once again. The word itself is from French and means "already seen." Though there is a common misconception among people that Déjà Vu is a very rare occurrence, in reality, this apparently mysterious experience happens to almost 97 percent of people's lives. Thus, it is a very common thing that will be felt by most people at least once in their lifetime.

What Is Déjà Vu?

As mentioned before, the word itself shows the very aspect of Déjà Vu that it's already seen. Suppose you are having a deep conversation with your friend, family, or a stranger, but you feel like this is not the first time you are having this conversation; you already know the topics and outcomes, as if you are living the same moment that you have lived before.

On the other hand, you might be visiting a new place, maybe a new city that you have never visited, but the places, houses, and overall atmosphere feel very recognizable. You suddenly feel that you have visited that place before and have felt good or bad in the past, as if you are living a past in your present.

All in all, this kind of strange phenomenon that happens to people regularly, this kind of uncomfortable feeling which is felt by 97 percent of people in the world, is called Déjà Vu.

What Causes Déjà Vu?

The root cause of this strange phenomenon is believed to be a result that one place or any conversation or any situation is resembling the same kind of pattern or feelings that you have experienced and felt before, and in most cases, you yourself have forgotten that, but your brain has not, and it recreates this sense of familiarity, and you feel you are living in a paradox.

In other words, déjà vu occurs when two parts of your brain fail to communicate properly: the temporal lobe, which handles memories, and the hippocampus, which processes new experiences.

There are certain things that can cause Déjà Vu more than others, such as fatigue or sleep deprivation, stress, and anxiety, which can trigger the feeling of Déjà Vu, as this pressure on your mental and physical health might pressure your brain and distort the recognition process. Other than that, migraine, dementia, and seizure can also cause Déjà Vu in a person.

Occasional déjà vu is generally harmless and not a cause for concern. However, if it happens frequently, lasts more than a few seconds, or is accompanied by other symptoms, it may be a good idea to seek medical advice.